Press releases

The press releases are available in Swedish when no translation exists.

The Board decides to convene an Extraordinary General Meeting

Chordate Medical Holding AB's (publ) ("Chordate") Board of Directors has today decided to convene an Extraordinary General Meeting. The reason for the Extraordinary General Meeting is to decide on the election of a new Board member, Caroline Lundgren Brandberg, a decision on the establishment of a Nomination Committee and a decision on a new option program for key persons in the company. The formal notice must be published no later than September 21st, where full information on each decision point will be included.

The Board's decision to convene an Extraordinary General Meeting relates to three matters. Shareholders representing more than 50 percent of the ownership propose that Caroline Lundgren Brandberg take a seat on the board. The matter of the Nomination Committee intends to formalize such a review body before the next Annual General Meeting. The option program is intended to give the company the opportunity to be able to attract and retain the right competence in the company.

This disclosure was submitted for publication, through the contact person below, on September 14th 2021 at 16:40 am CET.

For more information, please contact:

Anders Weilandt, VD
anders.weilandt@chordate.com
Phone: +46 (0) 733 87 42 77

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM - SME (ticker: CMH). Read more at
https://www.chordate.com/en/

We are a Swedish medical technology company listed on NGM Nordic SME.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact